Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mineralys Therapeutics, Inc.

14.25
+0.75005.56%
Post-market: 14.450.1999+1.40%19:56 EDT
Volume:1.30M
Turnover:18.26M
Market Cap:894.88M
PE:-3.89
High:14.40
Open:13.87
Low:13.53
Close:13.50
Loading ...

Mineralys Therapeutics Prices $175 Million Share Offering

MT Newswires Live
·
12 Mar

BRIEF-Mineralys Therapeutics Announces Pricing Of $175.0 Million Underwritten Public Offering Of Common Stock

Reuters
·
12 Mar

Mineralys Therapeutics Inc - Pricing of Underwritten Public Offering of 12.96 Mln Shares of Common Stock at $13.50 per Share

THOMSON REUTERS
·
12 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney

Reuters
·
12 Mar

Bank of America Securities Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)

TIPRANKS
·
11 Mar

BUZZ-Mineralys launches $250 mln equity offering to fund blood pressure drug; shares dip

Reuters
·
11 Mar

Mineralys Therapeutics Launches $250 Million Public Offering of Shares

MT Newswires Live
·
11 Mar

Mineralys Therapeutics Inc - Commenced an Underwritten Public Offering of $250.0 Mln of Shares of Its Common Stock

THOMSON REUTERS
·
11 Mar

Top Midday Gainers

MT Newswires Live
·
11 Mar

BUZZ-Mineralys hits near two-year high as blood pressure drug meets trial goals

Reuters
·
11 Mar

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

Benzinga
·
11 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Willis Lease Finance, CME Group

Reuters
·
11 Mar

Buy Rating Affirmed for Mineralys Therapeutics, Inc. Due to Promising Lorundrostat Study Outcomes

TIPRANKS
·
10 Mar

Promising Potential of Lorundrostat Drives Buy Rating for Mineralys Therapeutics, Inc.

TIPRANKS
·
10 Mar

Mineralys' drug for persistent hypertension succeeds in two trials

Reuters
·
10 Mar

Mineralys Therapeutics Up Over 55%, on Pace for Record Percent Increase -- Data Talk

Dow Jones
·
10 Mar